Patent 11633493 was granted and assigned to Daiichi Sankyo on April, 2023 by the United States Patent and Trademark Office.
As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L